#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=Ultrasensitive Detection of Prions by saPMCA
#Text=[0161] Sensitivity of detection after automated PMCA was analyzed by comparing the signal intensity in Western blots before and after amplification.
1-1	0-14	Ultrasensitive	_	_	
1-2	15-24	Detection	_	_	
1-3	25-27	of	_	_	
1-4	28-34	Prions	_	_	
1-5	35-37	by	_	_	
1-6	38-44	saPMCA	_	_	
1-7	45-46	[	_	_	
1-8	46-50	0161	_	_	
1-9	50-51	]	_	_	
1-10	52-63	Sensitivity	_	_	
1-11	64-66	of	_	_	
1-12	67-76	detection	_	_	
1-13	77-82	after	_	_	
1-14	83-92	automated	_	_	
1-15	93-97	PMCA	_	_	
1-16	98-101	was	_	_	
1-17	102-110	analyzed	_	_	
1-18	111-113	by	_	_	
1-19	114-123	comparing	_	_	
1-20	124-127	the	_	_	
1-21	128-134	signal	_	_	
1-22	135-144	intensity	_	_	
1-23	145-147	in	_	_	
1-24	148-155	Western	_	_	
1-25	156-161	blots	_	_	
1-26	162-168	before	_	_	
1-27	169-172	and	_	_	
1-28	173-178	after	_	_	
1-29	179-192	amplification	_	_	
1-30	192-193	.	_	_	

#Text=It was determined that 140 PMCA cycles enabled detection of PrP.sup.Sc in as little as a 6.6 million-fold dilution of 263K scrapie brain.
2-1	194-196	It	_	_	
2-2	197-200	was	_	_	
2-3	201-211	determined	_	_	
2-4	212-216	that	_	_	
2-5	217-220	140	_	_	
2-6	221-225	PMCA	_	_	
2-7	226-232	cycles	_	_	
2-8	233-240	enabled	_	_	
2-9	241-250	detection	_	_	
2-10	251-253	of	_	_	
2-11	254-264	PrP.sup.Sc	_	_	
2-12	265-267	in	_	_	
2-13	268-270	as	_	_	
2-14	271-277	little	_	_	
2-15	278-280	as	_	_	
2-16	281-282	a	_	_	
2-17	283-286	6.6	_	_	
2-18	287-299	million-fold	_	_	
2-19	300-308	dilution	_	_	
2-20	309-311	of	_	_	
2-21	312-316	263K	_	_	
2-22	317-324	scrapie	_	_	
2-23	325-330	brain	_	_	
2-24	330-331	.	_	_	

#Text=An equivalent quantity of PrP.sup.Sc was detected without PMCA in a 1,000-fold dilution of the same material, indicating that the increase of sensitivity under these conditions was approximately 6,600-fold.
#Text=[0162] During these studies, it was noted that the efficiency of amplification started to decrease after around 150 cycles (75 h of incubation).
3-1	332-334	An	_	_	
3-2	335-345	equivalent	_	_	
3-3	346-354	quantity	_	_	
3-4	355-357	of	_	_	
3-5	358-368	PrP.sup.Sc	_	_	
3-6	369-372	was	_	_	
3-7	373-381	detected	_	_	
3-8	382-389	without	_	_	
3-9	390-394	PMCA	_	_	
3-10	395-397	in	_	_	
3-11	398-399	a	_	_	
3-12	400-405	1,000	_	_	
3-13	405-406	-	_	_	
3-14	406-410	fold	_	_	
3-15	411-419	dilution	_	_	
3-16	420-422	of	_	_	
3-17	423-426	the	_	_	
3-18	427-431	same	_	_	
3-19	432-440	material	_	_	
3-20	440-441	,	_	_	
3-21	442-452	indicating	_	_	
3-22	453-457	that	_	_	
3-23	458-461	the	_	_	
3-24	462-470	increase	_	_	
3-25	471-473	of	_	_	
3-26	474-485	sensitivity	_	_	
3-27	486-491	under	_	_	
3-28	492-497	these	_	_	
3-29	498-508	conditions	_	_	
3-30	509-512	was	_	_	
3-31	513-526	approximately	_	_	
3-32	527-532	6,600	_	_	
3-33	532-533	-	_	_	
3-34	533-537	fold	_	_	
3-35	537-538	.	_	_	
3-36	539-540	[	*[1]	4-8[2_1]	
3-37	540-544	0162	*[1]	_	
3-38	544-545	]	*[1]	_	
3-39	546-552	During	*[1]	_	
3-40	553-558	these	*[1]	_	
3-41	559-566	studies	*[1]	_	
3-42	566-567	,	*[1]	_	
3-43	568-570	it	*[1]	_	
3-44	571-574	was	*[1]	_	
3-45	575-580	noted	*[1]	_	
3-46	581-585	that	*[1]	_	
3-47	586-589	the	*[1]	_	
3-48	590-600	efficiency	*[1]	_	
3-49	601-603	of	*[1]	_	
3-50	604-617	amplification	*[1]	_	
3-51	618-625	started	*[1]	_	
3-52	626-628	to	*[1]	_	
3-53	629-637	decrease	*[1]	_	
3-54	638-643	after	*[1]	_	
3-55	644-650	around	*[1]	_	
3-56	651-654	150	*[1]	_	
3-57	655-661	cycles	*[1]	_	
3-58	662-663	(	*[1]	_	
3-59	663-665	75	*[1]	_	
3-60	666-667	h	*[1]	_	
3-61	668-670	of	*[1]	_	
3-62	671-681	incubation	*[1]	_	
3-63	681-682	)	*[1]	_	
3-64	682-683	.	*[1]	_	

#Text=The inventors discovered that the reason for this problem is the inactivation of the material by continuous incubation at 37.degree.
4-1	684-687	The	_	_	
4-2	688-697	inventors	_	_	
4-3	698-708	discovered	_	_	
4-4	709-713	that	_	_	
4-5	714-717	the	_	_	
4-6	718-724	reason	_	_	
4-7	725-728	for	_	_	
4-8	729-733	this	*[2]	_	
4-9	734-741	problem	*[2]	_	
4-10	742-744	is	_	_	
4-11	745-748	the	_	_	
4-12	749-761	inactivation	_	_	
4-13	762-764	of	_	_	
4-14	765-768	the	_	_	
4-15	769-777	material	_	_	
4-16	778-780	by	_	_	
4-17	781-791	continuous	_	_	
4-18	792-802	incubation	_	_	
4-19	803-805	at	_	_	
4-20	806-808	37	_	_	
4-21	808-809	.	_	_	
4-22	809-815	degree	_	_	
4-23	815-816	.	_	_	

#Text=C.
5-1	817-818	C	_	_	
5-2	818-819	.	_	_	

#Text=It is likely that incubation may have a negative effect on the stability of PrP.sup.C substrate or other brain cofactors essential to catalyze the conversion.
6-1	820-822	It	_	_	
6-2	823-825	is	_	_	
6-3	826-832	likely	_	_	
6-4	833-837	that	_	_	
6-5	838-848	incubation	_	_	
6-6	849-852	may	_	_	
6-7	853-857	have	_	_	
6-8	858-859	a	_	_	
6-9	860-868	negative	_	_	
6-10	869-875	effect	_	_	
6-11	876-878	on	_	_	
6-12	879-882	the	_	_	
6-13	883-892	stability	_	_	
6-14	893-895	of	_	_	
6-15	896-905	PrP.sup.C	_	_	
6-16	906-915	substrate	_	_	
6-17	916-918	or	_	_	
6-18	919-924	other	_	_	
6-19	925-930	brain	_	_	
6-20	931-940	cofactors	_	_	
6-21	941-950	essential	_	_	
6-22	951-953	to	_	_	
6-23	954-962	catalyze	_	_	
6-24	963-966	the	_	_	
6-25	967-977	conversion	_	_	
6-26	977-978	.	_	_	

#Text=This conclusion was based on an experiment in which the amplification efficiency was dramatically reduced when the 10% normal brain homogenate was pre-incubated (with our without sonication) during 72 h prior to the beginning of PMCA amplifications.
7-1	979-983	This	_	_	
7-2	984-994	conclusion	_	_	
7-3	995-998	was	_	_	
7-4	999-1004	based	_	_	
7-5	1005-1007	on	_	_	
7-6	1008-1010	an	_	_	
7-7	1011-1021	experiment	_	_	
7-8	1022-1024	in	_	_	
7-9	1025-1030	which	_	_	
7-10	1031-1034	the	_	_	
7-11	1035-1048	amplification	_	_	
7-12	1049-1059	efficiency	_	_	
7-13	1060-1063	was	_	_	
7-14	1064-1076	dramatically	_	_	
7-15	1077-1084	reduced	_	_	
7-16	1085-1089	when	_	_	
7-17	1090-1093	the	_	_	
7-18	1094-1097	10%	_	_	
7-19	1098-1104	normal	_	_	
7-20	1105-1110	brain	_	_	
7-21	1111-1121	homogenate	_	_	
7-22	1122-1125	was	_	_	
7-23	1126-1139	pre-incubated	_	_	
7-24	1140-1141	(	_	_	
7-25	1141-1145	with	_	_	
7-26	1146-1149	our	_	_	
7-27	1150-1157	without	_	_	
7-28	1158-1168	sonication	_	_	
7-29	1168-1169	)	_	_	
7-30	1170-1176	during	_	_	
7-31	1177-1179	72	_	_	
7-32	1180-1181	h	_	_	
7-33	1182-1187	prior	_	_	
7-34	1188-1190	to	_	_	
7-35	1191-1194	the	_	_	
7-36	1195-1204	beginning	_	_	
7-37	1205-1207	of	_	_	
7-38	1208-1212	PMCA	_	_	
7-39	1213-1227	amplifications	_	_	
7-40	1227-1228	.	_	_	

#Text=This result was motivation to develop a new technology called serial automated PMCA (saPMCA) in order to further increase sensitivity of detection.
8-1	1229-1233	This	_	_	
8-2	1234-1240	result	_	_	
8-3	1241-1244	was	_	_	
8-4	1245-1255	motivation	_	_	
8-5	1256-1258	to	_	_	
8-6	1259-1266	develop	_	_	
8-7	1267-1268	a	_	_	
8-8	1269-1272	new	_	_	
8-9	1273-1283	technology	_	_	
8-10	1284-1290	called	_	_	
8-11	1291-1297	serial	_	_	
8-12	1298-1307	automated	_	_	
8-13	1308-1312	PMCA	_	_	
8-14	1313-1314	(	_	_	
8-15	1314-1320	saPMCA	_	_	
8-16	1320-1321	)	_	_	
8-17	1322-1324	in	_	_	
8-18	1325-1330	order	_	_	
8-19	1331-1333	to	_	_	
8-20	1334-1341	further	_	_	
8-21	1342-1350	increase	_	_	
8-22	1351-1362	sensitivity	_	_	
8-23	1363-1365	of	_	_	
8-24	1366-1375	detection	_	_	
8-25	1375-1376	.	_	_	

#Text=This technology consists of performing a series of up to 144 PMCA cycles each.
9-1	1377-1381	This	_	_	
9-2	1382-1392	technology	_	_	
9-3	1393-1401	consists	_	_	
9-4	1402-1404	of	_	_	
9-5	1405-1415	performing	_	_	
9-6	1416-1417	a	_	_	
9-7	1418-1424	series	_	_	
9-8	1425-1427	of	_	_	
9-9	1428-1430	up	_	_	
9-10	1431-1433	to	_	_	
9-11	1434-1437	144	_	_	
9-12	1438-1442	PMCA	_	_	
9-13	1443-1449	cycles	_	_	
9-14	1450-1454	each	_	_	
9-15	1454-1455	.	_	_	

#Text=After the end of a first round of 144 PMCA cycles, samples are diluted 10-fold into fresh 10% normal brain homogenate and another 144 (or less) PMCA cycles is performed. saPMCA resolves the problem of exhaustion of the substrate and enables to maintain the exponential conversion of PrP.
10-1	1456-1461	After	_	_	
10-2	1462-1465	the	_	_	
10-3	1466-1469	end	_	_	
10-4	1470-1472	of	_	_	
10-5	1473-1474	a	_	_	
10-6	1475-1480	first	_	_	
10-7	1481-1486	round	_	_	
10-8	1487-1489	of	_	_	
10-9	1490-1493	144	_	_	
10-10	1494-1498	PMCA	_	_	
10-11	1499-1505	cycles	_	_	
10-12	1505-1506	,	_	_	
10-13	1507-1514	samples	_	_	
10-14	1515-1518	are	_	_	
10-15	1519-1526	diluted	_	_	
10-16	1527-1529	10	_	_	
10-17	1529-1530	-	_	_	
10-18	1530-1534	fold	_	_	
10-19	1535-1539	into	_	_	
10-20	1540-1545	fresh	_	_	
10-21	1546-1549	10%	_	_	
10-22	1550-1556	normal	_	_	
10-23	1557-1562	brain	_	_	
10-24	1563-1573	homogenate	_	_	
10-25	1574-1577	and	_	_	
10-26	1578-1585	another	_	_	
10-27	1586-1589	144	_	_	
10-28	1590-1591	(	_	_	
10-29	1591-1593	or	_	_	
10-30	1594-1598	less	_	_	
10-31	1598-1599	)	_	_	
10-32	1600-1604	PMCA	_	_	
10-33	1605-1611	cycles	_	_	
10-34	1612-1614	is	_	_	
10-35	1615-1624	performed	_	_	
10-36	1624-1625	.	_	_	
10-37	1626-1632	saPMCA	_	_	
10-38	1633-1641	resolves	_	_	
10-39	1642-1645	the	_	_	
10-40	1646-1653	problem	_	_	
10-41	1654-1656	of	_	_	
10-42	1657-1667	exhaustion	_	_	
10-43	1668-1670	of	_	_	
10-44	1671-1674	the	_	_	
10-45	1675-1684	substrate	_	_	
10-46	1685-1688	and	_	_	
10-47	1689-1696	enables	_	_	
10-48	1697-1699	to	_	_	
10-49	1700-1708	maintain	_	_	
10-50	1709-1712	the	_	_	
10-51	1713-1724	exponential	_	_	
10-52	1725-1735	conversion	_	_	
10-53	1736-1738	of	_	_	
10-54	1739-1742	PrP	_	_	
10-55	1742-1743	.	_	_	

#Text=Two successive rounds of PMCA cycling separated by a 10-fold dilution of the amplified samples into fresh 10% normal brain homogenate, led to a dramatic increase in sensitivity.
11-1	1744-1747	Two	_	_	
11-2	1748-1758	successive	_	_	
11-3	1759-1765	rounds	_	_	
11-4	1766-1768	of	_	_	
11-5	1769-1773	PMCA	_	_	
11-6	1774-1781	cycling	_	_	
11-7	1782-1791	separated	_	_	
11-8	1792-1794	by	_	_	
11-9	1795-1796	a	_	_	
11-10	1797-1799	10	_	_	
11-11	1799-1800	-	_	_	
11-12	1800-1804	fold	_	_	
11-13	1805-1813	dilution	_	_	
11-14	1814-1816	of	_	_	
11-15	1817-1820	the	_	_	
11-16	1821-1830	amplified	_	_	
11-17	1831-1838	samples	_	_	
11-18	1839-1843	into	_	_	
11-19	1844-1849	fresh	_	_	
11-20	1850-1853	10%	_	_	
11-21	1854-1860	normal	_	_	
11-22	1861-1866	brain	_	_	
11-23	1867-1877	homogenate	_	_	
11-24	1877-1878	,	_	_	
11-25	1879-1882	led	_	_	
11-26	1883-1885	to	_	_	
11-27	1886-1887	a	_	_	
11-28	1888-1896	dramatic	_	_	
11-29	1897-1905	increase	_	_	
11-30	1906-1908	in	_	_	
11-31	1909-1920	sensitivity	_	_	
11-32	1920-1921	.	_	_	

#Text=The experiment consisted of performing a first round of 96 PMCA cycles in which PrP.sup.Sc signal was detected up to the 3.1.times.10.sup.6-fold dilution of scrapie brain.
12-1	1922-1925	The	_	_	
12-2	1926-1936	experiment	_	_	
12-3	1937-1946	consisted	_	_	
12-4	1947-1949	of	_	_	
12-5	1950-1960	performing	_	_	
12-6	1961-1962	a	_	_	
12-7	1963-1968	first	_	_	
12-8	1969-1974	round	_	_	
12-9	1975-1977	of	_	_	
12-10	1978-1980	96	_	_	
12-11	1981-1985	PMCA	_	_	
12-12	1986-1992	cycles	_	_	
12-13	1993-1995	in	_	_	
12-14	1996-2001	which	_	_	
12-15	2002-2012	PrP.sup.Sc	_	_	
12-16	2013-2019	signal	_	_	
12-17	2020-2023	was	_	_	
12-18	2024-2032	detected	_	_	
12-19	2033-2035	up	_	_	
12-20	2036-2038	to	_	_	
12-21	2039-2042	the	_	_	
12-22	2043-2046	3.1	_	_	
12-23	2046-2047	.	_	_	
12-24	2047-2052	times	_	_	
12-25	2052-2055	.10	_	_	
12-26	2055-2056	.	_	_	
12-27	2056-2059	sup	_	_	
12-28	2059-2061	.6	_	_	
12-29	2061-2062	-	_	_	
12-30	2062-2066	fold	_	_	
12-31	2067-2075	dilution	_	_	
12-32	2076-2078	of	_	_	
12-33	2079-2086	scrapie	_	_	
12-34	2087-2092	brain	_	_	
12-35	2092-2093	.	_	_	

#Text=Thereafter, this and all the successive dilutions in which no PrP.sup.Sc signal was detected were diluted 10-fold into normal brain homogenate and subjected to a new round of 118 PMCA cycles.
13-1	2094-2104	Thereafter	_	_	
13-2	2104-2105	,	_	_	
13-3	2106-2110	this	_	_	
13-4	2111-2114	and	_	_	
13-5	2115-2118	all	_	_	
13-6	2119-2122	the	_	_	
13-7	2123-2133	successive	_	_	
13-8	2134-2143	dilutions	_	_	
13-9	2144-2146	in	_	_	
13-10	2147-2152	which	_	_	
13-11	2153-2155	no	_	_	
13-12	2156-2166	PrP.sup.Sc	_	_	
13-13	2167-2173	signal	_	_	
13-14	2174-2177	was	_	_	
13-15	2178-2186	detected	_	_	
13-16	2187-2191	were	_	_	
13-17	2192-2199	diluted	_	_	
13-18	2200-2202	10	_	_	
13-19	2202-2203	-	_	_	
13-20	2203-2207	fold	_	_	
13-21	2208-2212	into	_	_	
13-22	2213-2219	normal	_	_	
13-23	2220-2225	brain	_	_	
13-24	2226-2236	homogenate	_	_	
13-25	2237-2240	and	_	_	
13-26	2241-2250	subjected	_	_	
13-27	2251-2253	to	_	_	
13-28	2254-2255	a	_	_	
13-29	2256-2259	new	_	_	
13-30	2260-2265	round	_	_	
13-31	2266-2268	of	_	_	
13-32	2269-2272	118	_	_	
13-33	2273-2277	PMCA	_	_	
13-34	2278-2284	cycles	_	_	
13-35	2284-2285	.	_	_	

#Text=This second round of PMCA enabled detection of PrP.sup.Sc up to the 5.times.10.sup.10-fold dilution of scrapie-infected hamster brain.
14-1	2286-2290	This	_	_	
14-2	2291-2297	second	_	_	
14-3	2298-2303	round	_	_	
14-4	2304-2306	of	_	_	
14-5	2307-2311	PMCA	_	_	
14-6	2312-2319	enabled	_	_	
14-7	2320-2329	detection	_	_	
14-8	2330-2332	of	_	_	
14-9	2333-2343	PrP.sup.Sc	_	_	
14-10	2344-2346	up	_	_	
14-11	2347-2349	to	_	_	
14-12	2350-2353	the	_	_	
14-13	2354-2355	5	_	_	
14-14	2355-2356	.	_	_	
14-15	2356-2361	times	_	_	
14-16	2361-2364	.10	_	_	
14-17	2364-2365	.	_	_	
14-18	2365-2368	sup	_	_	
14-19	2368-2371	.10	_	_	
14-20	2371-2372	-	_	_	
14-21	2372-2376	fold	_	_	
14-22	2377-2385	dilution	_	_	
14-23	2386-2388	of	_	_	
14-24	2389-2405	scrapie-infected	_	_	
14-25	2406-2413	hamster	_	_	
14-26	2414-2419	brain	_	_	
14-27	2419-2420	.	_	_	

#Text=By comparing the signal intensity of PrP.sup.Sc with or without PMCA, the increase of sensitivity was around 10-million fold.
15-1	2421-2423	By	_	_	
15-2	2424-2433	comparing	_	_	
15-3	2434-2437	the	_	_	
15-4	2438-2444	signal	_	_	
15-5	2445-2454	intensity	_	_	
15-6	2455-2457	of	_	_	
15-7	2458-2468	PrP.sup.Sc	_	_	
15-8	2469-2473	with	_	_	
15-9	2474-2476	or	_	_	
15-10	2477-2484	without	_	_	
15-11	2485-2489	PMCA	_	_	
15-12	2489-2490	,	_	_	
15-13	2491-2494	the	_	_	
15-14	2495-2503	increase	_	_	
15-15	2504-2506	of	_	_	
15-16	2507-2518	sensitivity	_	_	
15-17	2519-2522	was	_	_	
15-18	2523-2529	around	_	_	
15-19	2530-2532	10	_	_	
15-20	2532-2533	-	_	_	
15-21	2533-2540	million	_	_	
15-22	2541-2545	fold	_	_	
15-23	2545-2546	.	_	_	

#Text=This sensitivity can be further increased by performing more rounds of saPMCA.
16-1	2547-2551	This	_	_	
16-2	2552-2563	sensitivity	_	_	
16-3	2564-2567	can	_	_	
16-4	2568-2570	be	_	_	
16-5	2571-2578	further	_	_	
16-6	2579-2588	increased	_	_	
16-7	2589-2591	by	_	_	
16-8	2592-2602	performing	_	_	
16-9	2603-2607	more	_	_	
16-10	2608-2614	rounds	_	_	
16-11	2615-2617	of	_	_	
16-12	2618-2624	saPMCA	_	_	
16-13	2624-2625	.	_	_	

#Text=Example 5
#Text=Infinite Prion Replication In Vitro by saPMCA
17-1	2626-2633	Example	_	_	
17-2	2634-2635	5	_	_	
17-3	2636-2644	Infinite	_	_	
17-4	2645-2650	Prion	_	_	
17-5	2651-2662	Replication	_	_	
17-6	2663-2665	In	_	_	
17-7	2666-2671	Vitro	_	_	
17-8	2672-2674	by	_	_	
17-9	2675-2681	saPMCA	_	_	
